Your browser doesn't support javascript.
loading
Treatment of antibiotic refractory chronic pouchitis with JAK inhibitors and S1P receptor modulators: an ECCO CONFER Multicentre Case Series.
Ribaldone, Davide Giuseppe; Testa, Giulia; Verstockt, Bram; Molnar, Tamas; Savarino, Edoardo; Schmidt, Carsten; Vieujean, Sophie; Teich, Niels; Meianu, Corina; Juillerat, Pascal; Grellier, Nathan; Lobaton, Triana.
Afiliación
  • Ribaldone DG; Department of Medical Sciences, Division of Gastroenterology, University of Turin, Turin, Italy.
  • Testa G; Gastroenterology-U, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy.
  • Verstockt B; Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Molnar T; Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
  • Savarino E; University of Szeged, Hungary.
  • Schmidt C; Division of Gastroenterology, Department of Surgery Oncology and Gastroenterology DiSCOG, University of Padova, Padova, Italy.
  • Vieujean S; Medical Clinic II, Hospital Fulda, Fulda, Germany.
  • Teich N; Medical Faculty of the Friedrich Schiller University, Jena, Germany.
  • Meianu C; Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium.
  • Juillerat P; Medical Faculty of the Friedrich Schiller University, Jena, Germany.
  • Grellier N; Gastroenterology Practice, Leipzig, Germany.
  • Lobaton T; Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
J Crohns Colitis ; 2023 Nov 15.
Article en En | MEDLINE | ID: mdl-37965867
BACKGROUND AND AIMS: Data regarding effectiveness and safety of JAK inhibitors and S1P receptor modulators in antibiotic refractory chronic pouchitis (CARP) are lacking. METHODS: This ECCO-CONFER project retrospectively collected JAK inhibitors or S1P receptor modulators treatments for CARP with at least 3-months follow up. The outcomes included corticosteroid and antibiotics-free clinical response and remission at three and twelve months, trend in mPDAI, endoscopic PDAI, CRP and calprotectin. RESULTS: Seventeen treatments in 15 patients were collected. Previous pouchitis treatments included infliximab (5/15), adalimumab (4/15), vedolizumab (9/15), and ustekinumab (5/15). Pooling data on JAK inhibitors (8 tofacitinib, 1 filgotinib and 6 upadacitinib), after 3 months (T3), steroid and antibiotics-free clinical response was achieved in 53.3% (8/15), steroid and antibiotics-free clinical remission was achieved in 40% (6/15). Of the patients with at least 12 months of follow-up, steroid and antibiotics-free clinical response was achieved in 50% (3/6) and remission in one patient (16.7%), endoscopic response in 50% (3/6), endoscopic remission in 50% (3/6). Of the two ozanimod treatments at T3, steroid and antibiotics-free clinical response was achieved in one patient, without remission; both discontinued ozanimod before T12. No side effects reported. CONCLUSIONS: Small molecules may represent a suitable option for CARP refractory to multiple biologics, deserving further investigation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Crohns Colitis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Crohns Colitis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido